These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1093059

  • 1. Chemotherapy of prostatic cancer.
    Schmidt JD.
    Urol Clin North Am; 1975 Feb; 2(1):185-96. PubMed ID: 1093059
    [Abstract] [Full Text] [Related]

  • 2. [Predictive value of clinical, biochemical, hormonal and histologic parameters of the endocrine response in prostatic adenocarcinoma].
    Burgos FJ, Maganto E, Jiménez M, Mayayo T, Allona A, Mateos A, Escudero A, Romero-Aguirre C.
    Actas Urol Esp; 1988 Feb; 12(6):500-6. PubMed ID: 3232555
    [No Abstract] [Full Text] [Related]

  • 3. The EORTC Phase III trials in prostatic cancer.
    Robinson MR, Smith PH, Macaluso MP, Sylvester R, de Voogt H.
    Prog Clin Biol Res; 1985 Feb; 185A():243-9. PubMed ID: 3898132
    [No Abstract] [Full Text] [Related]

  • 4. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T, Haukaas S.
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Serum testosterone and acid phosphatase levels in patients with prostatic cancer treated with Estracyt].
    Németh A, Morvay J, Vécsei B.
    Orv Hetil; 1981 Apr 26; 122(17):1017-20. PubMed ID: 7022313
    [No Abstract] [Full Text] [Related]

  • 8. [Advanced prostatic cancer: therapeutic modalities].
    Faul P, Altwein JE.
    Dtsch Med Wochenschr; 1984 Dec 21; 109(51-52):1975-80. PubMed ID: 6391887
    [No Abstract] [Full Text] [Related]

  • 9. [Clinical effects of estramustine phosphate disodium (Estracyt) on prostatic cancer].
    Nishio S, Kishimoto T, Maekawa M, Kawakita J, Hayahara N, Yuki K, Morikawa Y, Yasumoto R, Kato Y, Funai K.
    Hinyokika Kiyo; 1986 Nov 21; 32(11):1763-70. PubMed ID: 3825823
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents.
    Akaza H, Isurugi K, Oishi Y, Kitajima K, Sawamura Y, Baba S, Yoshida K, Otani M, Harada M, Gunji A.
    Jpn J Clin Oncol; 1988 Dec 21; 18(4):343-55. PubMed ID: 2462651
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy of advanced prostatic cancer today.
    Murphy GP, Merrin CE.
    Prog Clin Biol Res; 1976 Dec 21; 6():285-99. PubMed ID: 139614
    [No Abstract] [Full Text] [Related]

  • 12. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ, Morales A.
    Can J Surg; 1983 Sep 21; 26(5):434-8. PubMed ID: 6351988
    [Abstract] [Full Text] [Related]

  • 13. [Chemotherapy of hormone-unresponsive prostatic cancer and its metastatic foci].
    Kotake T.
    Gan To Kagaku Ryoho; 1982 Mar 21; 9(3):387-96. PubMed ID: 6764105
    [Abstract] [Full Text] [Related]

  • 14. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J.
    Prog Clin Biol Res; 1987 Mar 21; 243B():229-34. PubMed ID: 3309983
    [No Abstract] [Full Text] [Related]

  • 15. Chemotherapy of hormonally unresponsive prostatic carcinoma.
    deKernion JB, Lindner A.
    Urol Clin North Am; 1984 May 21; 11(2):319-26. PubMed ID: 6233779
    [Abstract] [Full Text] [Related]

  • 16. Lessons from phase III-trials on the hormonal treatment of prostatic cancer. I: Results of EORTC-trials 30761 and 30762.
    de Voogt HJ, Pavone-Macaluso M, Smith PH, de Pauw M, Suciu S.
    Prog Clin Biol Res; 1988 May 21; 260():111-7. PubMed ID: 2966403
    [No Abstract] [Full Text] [Related]

  • 17. [Chemotherapy of prostatic cancer].
    Portnoĭ AS.
    Vopr Onkol; 1985 May 21; 31(9):3-12. PubMed ID: 2931901
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Cellular immunity in prostatic cancer modified by Cytonal, Estrazyt and Turisteron].
    Klebingat KJ, Panzig E, Lorenz G, Steinhauser I, Fiedler R.
    Z Urol Nephrol; 1987 Mar 21; 80(3):139-47. PubMed ID: 3300097
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.